A noninvasive wearable that tracks inflammation markers could let people with IBD and their clinicians detect rising disease activity earlier and potentially act before symptoms develop. This may make monitoring less...

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Risankizumab, IL-23 inhibitor, and Medications. Open the original article for the full details.

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease and Medications. The original article is from geneonline.com.

Vulvar Crohn’s is an uncommon but real extraintestinal manifestation that can cause painful skin changes and sometimes appears before GI Crohn’s is diagnosed. Knowing about it may speed diagnosis and lead to coordinated...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from firstwordpharma.com.

Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. Open the original article for the full...

The article centers on how Crohn’s affects Black people differently because of access barriers, stigma, and underrepresentation—issues that can influence diagnosis, disease severity, and quality of life.

Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Mirikizumab.

Long-term data matter because they show whether benefits and safety of a new biologic hold up beyond the initial trial period. For people with Crohn’s disease, sustained clinical remission and endoscopic healing are...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

Durable treatment responses matter to people with Crohn’s disease because sustained clinical remission and endoscopic improvement can mean fewer symptoms and less inflammation over time. Longer safety and durability data...

This article reports two-year data showing that mirikizumab (Omvoh) maintained clinical and endoscopic benefit for many people with moderate–severe Crohn’s disease, and that results across Phase 3 programs also support...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.

This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...

A new VEGFR2-targeted ultrasound contrast (BR55) has FDA fast track status for imaging active Crohn’s inflammation, which could eventually offer a non‑invasive way to monitor disease activity and treatment response...

Long-term results matter because they report whether an IL‑23 inhibitor (Omvoh) maintained clinical and endoscopic improvements through two years for people with moderate-to-severe Crohn’s disease, including some with...

This agent is being developed as a targeted, radiation-free ultrasound contrast to detect active bowel inflammation and angiogenesis in Crohn’s disease, which could improve non-invasive monitoring of disease activity and...

This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...

This roundup highlights new IBD research and real-world care issues that could influence future diagnosis, monitoring, and access to treatments. Findings on financial barriers and gaps in treat-to-target monitoring may...

This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results...

Based on the title and source metadata, this appears to be a patient story related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from wellandgood.com.

The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...

Early-stage work on a new bispecific antibody could point to a different immune-regulatory approach for treating inflammatory bowel disease. Patients and clinicians watching IBD drug development may find the mechanism...

Cure8 could only read part of this source from einnews.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

People with IBD — especially men — may have higher long-term risk of ischemic heart disease according to this large observational study. That could influence discussions about cardiovascular risk assessment and...

This article reports the start of a first-in-human trial testing extracellular vesicles as a new regenerative treatment for complex perianal fistulas in Crohn's disease, a hard-to-treat complication with limited options.

Researchers are exploring whether gut microbes differ in patients who develop fibrous strictures — a common, surgery-prone complication of Crohn’s disease — because that could help predict risk or point to new prevention...

Cure8 could only read part of this source from ajmc.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Gallstones, and Complications.

This signals new investigational IBD research focused on a novel immune pathway (TL1A/DR3) that could lead to future treatments. For people with Crohn’s/IBD, it’s an early-stage development to watch, but not an immediate...

Cure8 found this source from rollingout.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Symptoms and flares. Open the original article for the full details.

Researchers and companies continue exploring new immune-targeted therapies for IBD. A new DR3-targeted antibody could become a future treatment direction if clinical studies show benefit and safety. This announcement...

Local support groups can provide practical tips, emotional support, and community connections for people living with Crohn’s disease or ulcerative colitis. This meeting offers both in-person and virtual options, making...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from firstwordpharma.com.

Bowel obstruction is a potentially serious complication of Crohn’s disease that may need urgent treatment. The article summarizes common causes (strictures, adhesions, tumors), typical symptoms to watch for, and the...

This article describes implantable vagus nerve stimulators being studied as a way to reduce inflammation in autoimmune diseases, including Crohn’s disease. If effective, these devices could offer a non-drug option or...

Based on the title and source metadata, this appears to be a market or business news related to Crohn's disease, Inflammatory bowel disease, and Vedolizumab. The original article is from insights.citeline.com.

Surgical technique at the site of anastomosis can affect post-operative recurrence and recovery in Crohn’s disease. A simpler, faster stapled Kono-S might make this recurrence-reducing approach more accessible to...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from cureus.com.

Fundraising events like this support research and patient services for people with Crohn’s disease and ulcerative colitis. They also raise public awareness about IBD, which can reduce stigma and increase community...

Knowing the type of Crohn’s disease helps explain where symptoms come from and what treatments or procedures might be considered. The article links specific symptoms and complications to each anatomical pattern of...

Based on the title and source metadata, this appears to be a patient education related to Diet and lifestyle. The original article is from uk.style.yahoo.com.

New FDA approval adds another IL‑23p19 biologic option for moderate‑to‑severe Crohn’s disease and highlights two‑year efficacy data, which may affect treatment choices and future pediatric availability.

Cure8 could only read part of this source from morningstar.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Mirikizumab, and IL-23 inhibitor.

Based on the title and source metadata, this appears to be a biomarker study related to Inflammatory bowel disease, Colorectal Cancer Risk, and Research and clinical trials. The original article is from msn.com.

Based on the title and source metadata, this appears to be a patient story related to Mental health and quality of life. The original article is from msn.com.

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Procedures and surgery. Open the original article for the full details.

A test that more accurately predicts which IBD patients with pre-cancerous bowel changes will develop cancer could help target surveillance and treatment to those at higher risk and reduce unnecessary procedures for...

Based on the title and source metadata, this appears to be a patient education related to Complications. The original article is from msn.com.